Neuroepithelioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Neuroblastoma is a malignant tumor
that arises from neural crest cells, which give rise to the sympathetic nervous
system, and occurs mainly in children. The prognosis of neuroblastoma is
affected by various genetic anomalies, such as amplification of the oncogene
MYCN, numerical abnormalities of chromosomes and segmental chromosomal
anomalies (including loss from 1p, from 11q, or gains of 17q). Diagnosis is
based on elevated metabolites of urinary catecholamines and imaging of the
initial tumor by ultrasound, brain scan, or MRI. MIBG scintigraphy and
medullary analysis are useful for detecting metastases. Nephroblastoma is a
differential diagnosis. Bone pain and limp can be misinterpreted as synovitis
of the hip, and bilateral peri-orbital hematomas should not be mistaken for
maltreatment. The prognosis of neuroblastoma is poor for approximately 60% of
children over one year of age who present with metastatic disease at diagnosis,
even with intensive treatment. The five-year survival rate for children over
one year of age ranges from 95% for some localized tumors to 30% in cases of
metastatic neuroblastoma.
·
It represents about 10% of solid tumors in
infants and children under 15, with an annual incidence of approximately
1/70,000 in children in this class of age.
Thelansis’s “Neuroepithelioma Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Neuroepithelioma treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Neuroepithelioma across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Neuroepithelioma Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment